Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · IEX Real-Time Price · USD
6.93
+0.26 (3.90%)
At close: May 31, 2024, 4:00 PM
7.02
+0.09 (1.30%)
After-hours: May 31, 2024, 7:33 PM EDT
Orchestra BioMed Holdings Revenue
Orchestra BioMed Holdings had revenue of $2.22M in the twelve months ending March 31, 2024, down -42.16% year-over-year. Revenue in the quarter ending March 31, 2024 was $620.00K, a -46.74% decrease year-over-year. In the year 2023, Orchestra BioMed Holdings had annual revenue of $2.76M, a decrease of -21.88%.
Revenue (ttm)
$2.22M
Revenue Growth
-42.16%
P/S Ratio
111.92
Revenue / Employee
$39,571
Employees
56
Market Cap
248.01M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.76M | -773.00K | -21.88% |
Dec 31, 2022 | 3.53M | 4.32M | -551.79% |
Dec 31, 2021 | -782.00K | -6.49M | -113.71% |
Dec 31, 2020 | 5.70M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionOBIO News
- 11 days ago - Orchestra BioMed to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 20 days ago - Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 4 weeks ago - Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents - GlobeNewsWire
- 2 months ago - Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors - GlobeNewsWire
- 3 months ago - Orchestra BioMed to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients - GlobeNewsWire
- 5 months ago - Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients - GlobeNewsWire